On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > REGULATORY
REGULATORY
- Japan to Test Ivermectin for COVID-19: Prime Minister
May 7, 2020
- Japan Eyes May Approval for Avigan with Investigator-Led Study Data
May 7, 2020
- Japan Eyes Manufacturing Repatriation for 3 APIs: Extra Budget
May 1, 2020
- Japan Likely to Take FDA’s Anticipated EUA as Cue for “Special” Remdesivir OK
May 1, 2020
- Japan Can’t Give “Special Approval” for Avigan under Current Law: Abe
April 30, 2020
- Japan to Quickly Utilize “Special Approval” Scheme for Remdesivir after It’s OK’ed Overseas: Minister
April 30, 2020
- Antigen Test for New Coronavirus Filed in Japan: Minister
April 28, 2020
- Japan Might Approve Gilead’s Remdesivir for COVID-19 in May
April 28, 2020
- Japan Starts Assessing Performance of Antibody Test Kits: Minister
April 27, 2020
- Drug Makers Should Join in “Concerted National Effort” to Propel Regulatory Harmonization in Asia: Ex-PMDA Chair
April 27, 2020
- Japan Moving to Thwart Foreign Takeover of Drug, Medical Devices Makers
April 24, 2020
- In a First, Chuikyo to Be Streamed Live amid COVID-19 Outbreak
April 23, 2020
- Japan to Make Drug Review Time as Short as Possible for COVID-19: Minister
April 22, 2020
- Novartis’ Entresto, Mayzent Up for MHLW Panel Review in Round Robin Method
April 20, 2020
- Japan Declares Nationwide State of Emergency
April 17, 2020
- MSD’s 9-Valent HPV Vaccine Up for Review in 1st Online PAFSC Meeting
April 16, 2020
- Novartis’ Flawed and Delayed Inquiry Responses in Zolgensma Review “Extremely Unusual”: PMDA Report
April 16, 2020
- Osaka Pref., Osaka Univ. Form Alliance for COVID-19 Vaccine; AnGes Clinical Study Planned as Early as July
April 16, 2020
- MHLW Asks Drug Makers, Wholesalers to Reduce People Coming to Work by “at Least 70%”
April 15, 2020
- Health Minister Vows to Shorten Review Time for Avigan
April 14, 2020
ページ
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…